Skip to main content
Log in

Efficacy and Safety of Fentanyl Citrate Patch, Including a Low-Dose 0.5 mg Formulation, in Opioid-Naïve Patients with Cancer Pain

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and Objective

The use of transdermal fentanyl for opioid-naïve patients is restricted, however, transdermal fentanyl is a useful opioid analgesic for patients in whom oral administration is difficult or for those with renal failure. In this study, the efficacy and safety of fentanyl citrate patches was evaluated in opioid-naïve patients suffering from cancer pain.

Methods

An open-label uncontrolled study was conducted in opioid-naïve patients with cancer pain unable to be controlled by non-opioid analgesics. Fentanyl citrate patches starting at a low dose (0.5 mg/patch, corresponding to 6.25 μg/h fentanyl delivered) were applied once/day for up to 14 days. The analgesic effect was assessed every day from the visual analogue scale pain score and the number of doses of rescue medication. When improvement of the analgesic effect was “significant” or “moderate” at a certain dose for three consecutive days, the patient was classified as a “responder” and was considered to have “completed” the study.

Results

A fentanyl citrate patch was administered to 208 of 209 enrolled patients. In the full-analysis set, 87.0% of the patients were “responders” (95% confidence interval 81.7–91.3%). In 148 patients, the optimum dose was low (0.5 mg in 99, and 1 mg in 49), with patients finishing the study on days 4–8. Following dose escalation to 4 mg, respiratory depression occurred in one patient; however, this was considered a mild adverse event.

Conclusion

A low-dose fentanyl citrate patch was effective in the management of cancer pain in opioid-naïve patients and was well tolerated.

Study Registration

JPRN-JapicCTI-173717.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: World Health Organization, 2018. https://apps.who.int/medicinedocs/documents/s23605en/s23605en.pdf. Accessed 12 Feb 2020.

  2. Gisev N, Pearson SA, Larance B, Larney S, Blanch B, Degenhardt L. A population-based study of transdermal fentanyl initiation in Australian clinical practice. Eur J Clin Pharmacol. 2019;75:401–8.

    Article  CAS  PubMed  Google Scholar 

  3. Payne R. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. Semin Oncol. 1998;25:47–53.

    CAS  PubMed  Google Scholar 

  4. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58–e68.

    Article  CAS  PubMed  Google Scholar 

  5. Kang JH, Oh SY, Song SY, Lee HY, Kim JH, Lee KE, et al. The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. Korean J Intern Med. 2015;30:88–95.

    Article  CAS  PubMed  Google Scholar 

  6. Mercadante S, Porzio G, Ferrera P, Aielli F, Adile C, Ficorella C. Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. Curr Med Res Opin. 2010;26:2765–8.

    Article  CAS  PubMed  Google Scholar 

  7. Matsui T, Kojima T, Kojima H, Iwamoto N, Kure S, Uemura T, et al. Feasibility study of direct fentanyl patch introduction without prior opioid titration. Int J Clin Oncol. 2009;14:202–7.

    Article  PubMed  Google Scholar 

  8. van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WW. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin. 2003;19:457–69.

    Article  PubMed  Google Scholar 

  9. Mystakidou K, Tsilika E, Parpa E, Kouloulias V, Kouvaris I, Georgaki S, et al. Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl. Int J Cancer. 2003;107:486–92.

    Article  CAS  PubMed  Google Scholar 

  10. Vielvoye-Kerkmeer AP, Mattern C, Uitendaal MP. Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. J Pain Symptom Manag. 2000;19:185–92.

    Article  CAS  Google Scholar 

  11. Tassinari D, Sartori S, Tamburini E, Scarpi E, Tombesi P, Santelmo C, et al. Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Palliat Care. 2009;25:172–80.

    Article  PubMed  Google Scholar 

  12. Uchida E, Miyazaki T, Namiki A, Ogawa S, Kitajima T, Masuda Y, et al. Pharmacokinetic studies of the transdermal patch containing fentanyl citrate (HFT-290) in patients with cancer pain. J Clin Ther Med. 2010;26:335–51 (translated from Japanese).

    Google Scholar 

  13. Cancer Therapy Evaluation Program, Common Toxicity Criteria, Version 2.0, DCTD, NCI, NIH, DHHS, March 1998, revised March 23, 1998; published date: April 30, 1999. https://www.ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf. Accessed 12 Feb 2020.

  14. Imanaka K, Tominaga Y, Etropolski M, van Hove I, Ohsaka M, Wanibe M, et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin. 2013;29:1399–409.

    Article  CAS  PubMed  Google Scholar 

  15. Miyazaki T, Hanaoka K, Namiki A, Ogawa S, Kitajima T, Hosokawa T, et al. Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain. Clin Drug Investig. 2008;28:313–25.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank all the patients, investigators, and site staff involved in the study.

Author information

Authors and Affiliations

Authors

Contributions

SY and EU provided advice about the study design, conduct of the study, interpretation of the data, and making a clinical study report. TT, KO, FH, and YT contributed to the study concept and design, the conduct of the study, and data analysis and interpretation. All of the listed authors were involved in critical review and revision of the manuscript and approved the final content.

Corresponding author

Correspondence to Fumitaka Hashimoto.

Ethics declarations

Funding

This work was supported by Hisamitsu Pharmaceutical Co., Inc. (Japan), the manufacturer of the fentanyl citrate patch.

Conflict of interest

SY has received honoraria from Hisamitsu Pharmaceutical Co., Inc., The Nakatomi Foundation, Ayumi Pharmaceutical Corporation, Maruho Co., Ltd., Maruishi Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Teikoku Seiyaku Co., Ltd., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Shionogi & Co., Ltd., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Terumo Corporation, Mundipharma K.K., Taiho Phamaceutical Co., Ltd., Nippon Zoki Pharmaceutical Co., Ltd., MSD K.K., Taisho Toyama Pharmaceutical Co., Ltd., Covidien Japan Inc., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corporation, Baxter Limited, Japan Tobacco Inc., Otsuka Pharmaceutical Factory, Inc., and Daiken Medical Co., Ltd.; and received donations from Hisamitsu Pharmaceutical Co., Inc. EU has received honoraria as a medical consultant from Hisamitsu Pharmaceutical Co., Inc. TT, KO, FH, and YT are employees of Hisamitsu Pharmaceutical Co., Inc.

Ethics approval

This study was conducted in agreement with the principles of the Declaration of Helsinki and its later amendments, and Good Clinical Practice. The institutional review board at each participating center approved the study protocol.

Consent

All patients gave written, informed consent to participate.

Availability of data and material

The clinical study data are confidential.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamaguchi, S., Uchida, E., Terahara, T. et al. Efficacy and Safety of Fentanyl Citrate Patch, Including a Low-Dose 0.5 mg Formulation, in Opioid-Naïve Patients with Cancer Pain. Clin Drug Investig 40, 1041–1052 (2020). https://doi.org/10.1007/s40261-020-00965-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-020-00965-9

Navigation